Web Biotechnology Raises Pre-Series A Financing Round

Web Biotechnology Pte Ltd., a Singapore-based provider of cloud remote and personalized wearable ECG monitoring solutions, raised a Pre-series A financing round.

Singapore-based SGinnovate made the investment.

The company will use the funds to expand and scale into new markets, improve core backend Cloud database and AI systems, and research new generation improved ECG and vital sign wearables.

WEB produces the Spyder ECG, a medical grade ECG wearable that transmits continuously through a smartphone to a Cloud Database. Artificial Intelligence (AI) is then applied to the data to analyze ECG rhythm abnormalities in real-time. Its 24/7 “always on” system allows continuous patient ECG data transmission from anywhere in the world with a connected smartphone. Physicians can remotely log in securely into the database and report findings to patients from another connected device.
The company WEB has 2 product lines:
– the Spyder PRO, which is used to replace traditional hospital-based Holter ECG systems with a simple non-invasive wearable system for diagnostic ECG monitoring for extended periods up to a month. The PRO is widely available in many hospitals in Singapore, in Asia and the EU, is CE-Marked and HSA (Health Sciences Authority Singapore)-approved for remote cardiac rhythm monitoring. The Spyder PRO is available currently in over 30 countries worldwide through WEB’s distribution network; and
– the Spyder PERSONAL, an ECG Event monitor that allows anyone with a Spyder Wearable and connected smartphone to monitor his or her own cardiac rhythm. An App-enable smartphone allows continuous personal visualization of the ECG and an intuitive interface on the smartphone allows a 5-minute rhythm strip/event to be captured with this system into the cloud database. The user receives the captured event via immediate Email notification and the ECG strip can be sent to a physician for consultation. The Spyder PERSONAL is available as an online purchase.

FinSMEs

03/01/2018

 

Join the discussion